Aktiv Medical Systems offers the PenPal® Autoinjector platform

PenPal® seamlessly integrates exceptional design simplicity with superior performance, reliability, and platform versatility. Our vision is to leverage our capabilities and innovative PenPal® autoinjector technology to support pharmaceutical and biopharmaceutical partners in need of high-performance autoinjectors. We are dedicated to addressing underserved market segments that require injection dose volumes larger than 2.25 ml and/or high-viscosity formulations.

PenPal® Overview – Complexity Simplified!

Aktiv conceived a unique and differentiated approach, resulting in an extremely simple design architecture, consisting of very low part count and minimal mechanical interfaces between subsystems

  • Enabling, patented  “Direct Drive” technology

  • 6 molded parts and 4 off-the-shelf components

  • Device simplicity leads to superior reliability and versatility unmatched by any autoinjector

  • No other autoinjector can handle the entire range of standard drug containers & dose load

Technology results from $60M funded collaboration with the US government to develop a next-gen autoinjector

  • Designed to address the shortfalls of commercially available autoinjectors, including improving reliability, robustness, ease-of-use, along with true device platform versatility

  • Supporting the broadest range of complex injectable drug substances & characteristics

  • Tens of thousands of autoinjector samples were built and tested with a variety of drugs and under the most exacting testing conditions with two foundational goals

    • Demonstrate superior reliability of the technology platform

    • Perfect the simplicity of use and elimination of user errors

Direct Drive: Unlike any other commercially available autoinjector, PenPal® patented technology applies direct compressed gas pressure to the primary drug container for needle insertion, medication delivery and full needle retraction